• Home
• Patronate
• International Advisory Board
• Meetings
• Publications
• Aims
• Contact

Meetings

International Meeting on Dopamine Disease States

Mojácar (Almería)

October 18 - 22 1995

The content of this congress, together with other contributions on the topic, are collected in vol. 3 of the series "Strategies for studying brain disorders". (The book is also available in Spanish).

PROGRAMME

• Tomás Palomo, Spain.
  Opening Remarks.
• Erik Clavería, Spain.
  Neuroscience research in Spain and in collaboration with other countries.

S1. DOPAMINE-SCHIZOPHRENIA

• Sven-Ove Ögren, Sweden.
  The pharmacological profiles of new and awaited anti-psychotic agents.
• William Deakin, UK.
  Preclinical and clinical evidence for the excitatory amino-acids in schizophrenia.
• Bita Moghaddam, USA.
  Dopamine-glutamate interactions and Cognitive Deficits.
• Jeffrey M. Goldstein, USA.
  Pre-clinical tests that predict Clozapine-like atypical antipsychotic actions.
• S2. DOPAMINE-PARKINSON'S DISEASE.
• Jogren Scheel-Krüger, Denmark.
  Antagonism and reversal of the MPTP biochemical and behavioural effects in rodents and marmosets by NS 2214, a novel dopamine uptake inhibitor.
• Trevor Archer, Sweden.
  Dopaminergic-glutamatergic balance in the forebrain: functional studies of movement disorders in rats and mice
• Juan José López-Lozano, Spain.
  Experience with implantation of fetal mesencephalon in Parkinson's Disease: clinical results in 10 grade IV-V patients.
• Alberto Portera-Sánchez, Spain.
  Epidemiology, etiology and clinical perspectives of parkisonisms.

S3. DOPAMINE-ADDICTION AND NEUROCHEMISTRY

• Lew Seiden, USA.
  Methamphetamine (MA) engendered neurotoxicity to dopamine (DA) neurons: mechanism of action.
• Javier Fernández-Ruiz, Spain.
  Dopaminergic neurons as neurochemical substrates of neurobehavioral effects of marihuana: developmental and adult studies.
• Miguel Casas-Brugé, Spain.
  Relevance of dopamine systems in chemical addictions.
• Peter Kalivas, USA.
  Preclinical-clinical aspects of drug-and stress-induced psychosis.

S4. DOPAMINE DISORDER INTERACTIVE STUDIES

• David Jackson, Sweden.
  Clozapine: New biochemical and behavioural studies on its mechanism of action.
• Jorge Manzanares, Spain.
  Kappa opioid receptor regulation of nigrostriatal, mesolimbic, tuberoinfundibular and periventricular-hypophysial dopaminergic neurons in the male rat.
• Richard J. Beninger, Canada.
  Dopamine D1-like receptors and molecular mechanisms of incentive learning.
• Johan Luthman, Sweden.
  Functional and neurochemical responses to interventions in the developing dopamine system.
• Rik Broekkamp, The Netherlands.
  Role of dopamine-serotonin interrelationships in psychotropic drug effects.

S5. DOPAMINE-GENERAL CONSIDERATIONS

• Pierre Sokoloff, France.
  Multiple dopamine receptors: their significance for disease states.
• Bart Ellenbroek, The Netherlands.
  Dopamine and information processing.
• Klaus Ebmeier, UK.
  Imaging functional change and dopaminergic activity in depression.
• Ivan Izquierdo, Brasil.
  Synaptic mechanism in hippocampus, amygdala and enthorhinal cortex involved in memory formation, storage and expression.

S6. DOPAMINE DISEASE STATES

• Nancy Andreasen, USA.
  Neural substrates of frontal lobe function.
• Robin Murray, UK.
  Dementia praecox or developmental insanity: a new perspective on an old debate.
• George Koob, USA.
  Dopamine subtype receptor profiles in reward and abuse.
• Tim Crow, UK.
  The failure of the dopamine hypothesis and its consequences for the future direction of psychosis research.

STRATEGIES FOR STUDYING BRAIN DISORDERS

© 2009 Fundación Cerebro y Mente All rights reserved